HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis.

AuthorsSerena Bugatti, Ludovico De Stefano, Silvia Balduzzi, Maria Immacolata Greco, Terenzj Luvaro, Irene Cassaniti, Laura Bogliolo, Iolanda Mazzucchelli, Bernardo D'Onofrio, Michele di Lernia, Eleonora Mauric, Daniele Lilleri, Fausto Baldanti, Antonio Manzo, Carlomaurizio Montecucco
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 80 Issue 12 Pg. 1635-1638 (12 2021) ISSN: 1468-2060 [Electronic] England
PMID34172502 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Antirheumatic Agents
  • COVID-19 Vaccines
  • Glucocorticoids
  • BNT162 Vaccine
  • Methotrexate
Topics
  • Antirheumatic Agents (immunology)
  • Arthritis, Rheumatoid (drug therapy, immunology)
  • BNT162 Vaccine
  • COVID-19 (immunology, prevention & control)
  • COVID-19 Vaccines (immunology)
  • Female
  • Glucocorticoids (immunology)
  • Humans
  • Immunogenicity, Vaccine (drug effects)
  • Male
  • Methotrexate (immunology)
  • Middle Aged
  • SARS-CoV-2 (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: